现代医药卫生2017年1月第33卷第2期 J Mod Med Health, January2017,vol3,No.2 er leading to iNOS-mediated tumor cell lysis[J]. Oncoimmunology genetic program inhibits M2 macrophage polarization and enhances T cell 2014,3:e28926. infiltration into spontaneous mouse mammary tumor). Oncotarget, 2013 [28] Jeong SK, Yang K, Park YS, et al. Interferon gamma induced by resveratrol 4(12):2288-2 analog. HS-1793, reverses the properties of tumor associated macro- [40 Denardo DG, Barreto JB, Andreu P, et al. CD4(+)Tcells regulate pulmonary phages[J]. Int Immunopharmacol, 2014, 22(2): 303-310. etastasis of mammary carcinomas by enhancing protumor properties of 29Tsagozis P. Eriksson F, Pisa P. Zoledronic acid modulates antitumoral re- macrophages[J. Cancer Cell, 2009, 16(2): 91-102. sponses of prostate cancer-tumor associated macrophages J Cancer Immunol [41 Laoui D, an Overmeire E, De Baetselier P, et al. Functional relationship Immunother,2008,57(10):1451-1459 between tumor-associated macrophages and macrophage colony-stimu- [30]Ghosh D, Maiti TK. Effects of native and heat-denatured Abrus agglutinin lating factor as contributors to cancer progression J. Front Immunol on tumor-associated macrophages in Daltons lymphoma mice[l Immuno- 014,5:489 biology,2007,212(8):667-673 [42]Ostuni R, Kratochvill F. Murray PJ,et al. Macrophages and cancer: from [31 Watkins SK. Egilmez NK. Suttles J, et al. IL-12 rapidly alters the fune echanisms to therapeutic implications[J- Trends Immunol, 2015, 36(4) tional profile of tumor-associated and tumor-infiltrating macrophages in 229-239 vitro and in vivo. J Immunol, 2007, 178(3): 1357-1362 [43] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression [32 Beatty GL, Chiorean EG, Fishman MP,et al. CD40 agonists alter tumor nd metastasis[J Nat Med, 2013, 19(11): 1423-1437 stroma and show efficacy against pancreatic carcinoma in mice and hu- [44] Ruffell B, Affara NI, Coussens LM. Differential macrophage programming ns[J]. Science,2011,331(624):1612-1616 in the tumor microenvironment[J. Trends Immunol, 2012, 33(3): 119-126 [33] Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and [45] Weiner LM, Murray JC, Shuptrine CW, Antibody-based immunotherapy metastasis by inducing macrophage polarization and vessel normalization of cancer. Cell,2012,148(6):1081-1084 through downregulation of PIGFJ). Cancer Cell, 2011, 19(1): 31-44. [46] Nimmerjahn F, Gordan S, Lax A. FeyR dependent mechanisms of cyto- [34] Bak SP, Walters JJ, Takeya M, et al. Scavenger receptor-A-targeted toxic, agonistic, and neutralizing antibody activities[J). Trends Immunol varian tumor progression JJ 2015,36(6):325-336. Cancer res,2007,67(10):4783-4789. 47]Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fe receptors modulate [35] Lin EY, Li JF, Gnatovskiy L,et al. Macrophages regulate the angiogenic vivo eytotoxicity against tumor targets[J. Nat Med, 2000, 6(4): 443-446. switch in a mouse model of breast cancer[J). Cancer Res, 2006, 66(23): [48 Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 11238-11246. munotherapy in mice is mediated by macrophage FcgammaRl, Fo [36] Zhang W. Zhu XD, Sun HC,et al. Depletion of tumor-associated maRIll, and FcgammaRIV[J]. Blood, 2008, 112(4): 1205-1213 macrophages enhances the effect of sorafenib in metastatic liver cancer- [49] Otten MA, van der Bij GJ, Verbeek SJ,et al. Experimental antibody ther- models by antimetastatic and antiangiogenic effects[J]. Clin Cancer Res apy of liver metastases reveals functional redundancy between Fc gam- 2010,16(13):3420-3430 maRl and Fe gammaRIVU.J Immunol, 2008, 181(10): 6829-6836. [37) Shen KY, Song YC, Chen IH,et al. Depletion of tumor-associated [50 Park S,Jiang Z, Mortenson ED,et al. The therapeutic effect of anti- macrophages enhances the anti-tumor immunity induced by a Toll-like HER2/neu antibody depends on both innate and adaptive immunity[J] receptor agonist-conjugated peptide[J]. Hum Vaccin Immunother, 2014 Cancer Cell2010,18(2):160-170 l0(11):3241-3250 [51] Grugan KD, MeCabe FL, Kinder M, et al. Tumor-associated macrophages [38] Denardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity pre- promote invasion while retaining Fe-dependent anti-tumor function[J]. dicts breast cancer survival and functionally regulates response to Immunol,2012,189(11):5457-5466. chemotherapy[J). Cancer Discov, 2011, I(1): 54-67 (收稿日期:2016-09-25) 139 Mira E, Carmona-Rodriguez L, Tardaguila MA, et al. A lovastatin-elicited (上接第168页) 5 William Cs.癌症研究进展:第100届AACR年会见闻南娟,丁 件所限未引人国外文献数据进行分析,在肿瘤研究热 燕,译.中国肺癌杂志,2009,12(11):1188-1193 点和趋势捕捉上欠完整,后续可考虑开展联合研究,以向田玲,王冲、M四国与肿瘤研究进分子诊断与治疗杂志, 更全面客观地展现国内外某一研究领域的动态,为临床姜巩,魏风梅,严小杰,等,分子靶向抗肿瘤药物的研究进展 工作者提供更有价值的参考。 肿瘤药学,2016,6(3):182-184 参考文献 [8]苑光军.中医药防治肿瘤研究进展及思考辽宁中医药大学学报 2013,15(1):222-224 世界卫生组织.全球癌症报告抗癌,2015,28(2):44-45 9]段鸿芳,聂国辉.miR-494与肿瘤研究进展[-中国肿瘤,2015(2) 2]杨柯君.全球癌症状况最新数据更新门上海医药,2014,35(2):5. 122-126 [3] Chen wQ, Zheng Rs, Baade PD, et al. Cancer statistics in China, 20150- 10中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)临床 CA Cancer J Clin,2016,66(2):115-132 肿瘤学杂志,2011,16(10):929-946. 4]黄玮伊,许小兰,周乐明,等重庆市2013-2015年恶性肿瘤疾病谱1]傅兴圣,陈菲,刘训红,等.大黄化学成分与药理作用研究新进展 分析[现代医药卫生,2017-01-30[2016-12-05htp/ww. xdyyws 中国新药杂志,2011,20(16):1534-1538. com/newsinfo aspx?id=384 (收稿日期:2016-12-10)现代医药卫生 !"#$ 年 # 月第 %%卷第 ! 期 & '() '*) +*,-./!&,01,23 !"4$!5(-6%%!7(6! 件所限未引入国外文献数据进行分析!在肿瘤研究热 点和趋势捕捉上欠完整!后续可考虑开展联合研究!以 更全面客观地展现国内外某一研究领域的动态!为临床 工作者提供更有价值的参考" 参考文献 849 世界卫生组织6 全球癌症报告8&96 抗癌!!"4:!!;#!$%<<!<:6 8!9 杨柯君6 全球癌症状况最新数据更新8&96 上海医药!!"4<!%:#!$%:6 8%9 =/*0 >?!@/*0A BC!D,,)* EF!*. ,-6 =,0G*2 H.,.IH.IGH I0 =/I0,!!J4:8&96 =K =,0G*2 & =-I0!!L4M!MM#!$%44:!4%!6 8<9 黄玮伊!许小兰!周乐明!等6 重庆市 !"4%&!"4: 年恶性肿瘤疾病谱 分析8&96 现代医药卫生!!"4$!"4!%"8!"4M!4!!":96/..NOPQRRR6S)33RH6 G(TQ0*RHI0U(6,HNSVI)W%;<6 8:9 >I--I,T =C6 癌症研究进展%第 4"" 届 KK=B 年会见闻8&96 南娟!丁 燕!译6 中国肺癌杂志!!""X!4!#44$%44;;!44X%6 8M9 田玲!王冲6 'IG2(B7K 与肿瘤研究进展8&96 分子诊断与治疗杂志! !"4%!:#%$%!""!!":6 8$9 姜巩!魏凤梅 !严小杰 !等6 分子靶向抗肿瘤药物的研究进展8&96 肿瘤药学!!"4M!M#%$%4;!!4;<6 8;9 苑光军6 中医药防治肿瘤研究进展及思考8&96 辽宁中医药大学学报! !"4%!4:#4$%!!!!!!<6 8X9 段鸿芳!聂国辉6 TIB!<X< 与肿瘤研究进展8&96 中国肿瘤!!"4:#!$% 4!!!4!M6 84"9 中华人民共和国卫生部6 原发性肝癌诊疗规范 #!"44 年版$8&96 临床 肿瘤学杂志!!"44!4M#4"$%X!X!X<M6 8449 傅兴圣!陈菲!刘训红!等6 大黄化学成分与药理作用研究新进展8&96 中国新药杂志!!"44!!"#4M$%4:%<!4:%;6 #收稿日期%!"4M!4!!4"$ ,0G,0G*2 -*,)I0A .( I7YC!T*)I,.*) .1T(2 G*-- -3HIH8&96 Y0G(ITT10(-(A3! !"4<!%%*!;X!M6 8!;9 &*(0A CZ![,0A Z!E,2\ [C!*. ,-6 ]0.*2U*2(0 A,TT, I0)1G*) ^3 2*H_*2,.2(- ,0,-(A!+C!4$X%!2*_*2H*H ./* N2(N*2.I*H (U .1T(2 ,HH(GI,.*) T,G2(! N/,A*H8&9` ]0. ]TT10(N/,2T,G(-!!"4<!!!#!$%%"%!%4"6 8!X9 aH,A(bIH E!c2I\HH(0 d!EIH, E6 @(-*)2(0IG ,GI) T()1-,.*H ,0.I.1T(2,- 2*! HN(0H*H (U N2(H.,.* G,0G*2!.1T(2 ,HH(GI,.*) T,G2(N/,A*H8&96 =,0G*2 ]TT10(- ]TT10(./*2!!"";!:$#4"$%4<:4!4<:X6 8%"9 e/(H/ F!',I.I aZ6 cUU*G.H (U 0,.I_* ,0) /*,.!)*0,.12*) K^21H ,AA-1.I0I0 (0 .1T(2!,HH(GI,.*) T,G2(N/,A*H I0 F,-.(0"H -3TN/(T, TIG*8&96 ]TT10(! ^I(-(A3!!""$!!4!#;$%MM$!M$%6 8%49 >,.\I0H CZ!cAI-T*b 7Z!C1..-*H &!*. ,-6 ]f!4! 2,NI)-3 ,-.*2H ./* U10G! .I(0,- N2(UI-* (U .1T(2!,HH(GI,.*) ,0) .1T(2!I0UI-.2,.I0A T,G2(N/,A*H I0 _I.2( ,0) I0 _I_(8&96 & ]TT10(-!!LL$!4$;#%$%4%:$!4%M!6 8%!9 D*,..3 ef!=/I(2*,0 ce!dIH/T,0 'E!*. ,-6 =F<L ,A(0IH.H ,-.*2 .1T(2 H.2(T, ,0) H/(R *UUIG,G3 ,A,I0H. N,0G2*,.IG G,2GI0(T, I0 TIG* ,0) /1! T,0H8&96 CGI*0G*!!L44!%%4#M!<$%4M4!!4M4M6 8%%9 B(-03 =!',bb(0* '!a1A1*H C!*. ,-6 +Be I0/I^I.H .1T(2 A2(R./ ,0) T*.,H.,HIH ^3 I0)1GI0A T,G2(N/,A* N(-,2Ib,.I(0 ,0) _*HH*- 0(2T,-Ib,.I(0 ./2(1A/ )(R02*A1-,.I(0 (U E-ed8&96 =,0G*2 =*--!!L44!4X#4$%%4!<<6 8%<9 D,\ CE!>,-.*2H &&!a,\*3, '!*. ,-6 CG,_*0A*2 2*G*N.(2!K!.,2A*.*) -*1\(G3.* )*N-*.I(0 I0/I^I.H N*2I.(0*,- (_,2I,0 .1T(2 N2(A2*HHI(0 8&96 =,0G*2 B*H!!LL$!M$#4L$%<$;%!<$;X6 8%:9 fI0 c[!fI &d!e0,.(_H\I3 f!*. ,-6 ',G2(N/,A*H 2*A1-,.* ./* ,0AI(A*0IG HRI.G/ I0 , T(1H* T()*- (U ^2*,H. G,0G*28&96 =,0G*2 B*H!!LLM!MM#!%$% 44!%;!44!<M6 8%M9 @/,0A >!@/1 gF!C10 +=!*. ,-6 F*N-*.I(0 (U .1T(2!,HH(GI,.*) T,G2(N/,A*H *0/,0G*H ./* *UU*G. (U H(2,U*0I^ I0 T*.,H.,.IG -I_*2 G,0G*2! T()*-H ^3 ,0.IT*.,H.,.IG ,0) ,0.I,0AI(A*0IG *UU*G.H8&96 =-I0 =,0G*2 B*H! !L4L!4M#4%$%%<!L!%<%L6 8%$9 C/*0 Z[!C(0A [=!=/*0 ]+!*. ,-6 F*N-*.I(0 (U .1T(2!,HH(GI,.*) T,G2(N/,A*H *0/,0G*H ./* ,0.I!.1T(2 ITT10I.3 I0)1G*) ^3 , a(--!-I\* 2*G*N.(2 ,A(0IH.!G(0h1A,.*) N*N.I)* 8&96 +1T 5,GGI0 ]TT10(./*2!!L4<! 4L#44$%%!<4!%!:L6 8%;9 F*0,2)( Fe!D2*00,0 F&!B*S/*N,h c!*. ,-6 f*1\(G3.* G(TN-*SI.3 N2*! )IG.H ^2*,H. G,0G*2 H12_I_,- ,0) U10G.I(0,--3 2*A1-,.*H 2*HN(0H* .( G/*T(./*2,N38&96 =,0G*2 FIHG(_!!L44!4#4$%:<!M$6 8%X9 'I2, c!=,2T(0,!B()2IA1*b f!a,2),A1I-, 'K!*. ,-6 K -(_,H.,.I0!*-IGI.*) A*0*.IG N2(A2,T I0/I^I.H '! T,G2(N/,A* N(-,2Ib,.I(0 ,0) *0/,0G*H a G*-- I0UI-.2,.I(0 I0.( HN(0.,0*(1H T(1H* T,TT,23 .1T(2H8&96 Y0G(.,2A*.!!L4%! <#4!$%!!;;!!%L46 8<L9 F*0,2)( Fe!D,22*.( &D!K0)2*1 E!*. ,-6 =F<#i$ a G*--H2*A1-,.* N1-T(0,23 T*.,H.,HIH (U T,TT,23 G,2GI0(T,H ^3 *0/,0GI0A N2(.1T(2 N2(N*2.I*H (U T,G2(N/,A*H8&9` =,0G*2 =*--!!""X!4M#!$%X4!4"!` 8<49 f,(1I F!5,0 Y_*2T*I2* c!F* D,*.H*-I*2 E!*. ,-` d10G.I(0,- 2*-,.I(0H/IN ^*.R**0 .1T(2!,HH(GI,.*) T,G2(N/,A*H ,0) T,G2(N/,A* G(-(03!H.IT1! -,.I0A U,G.(2 ,H G(0.2I^1.(2H .( G,0G*2 N2(A2*HHI(08&9` d2(0. ]TT10(- ! !"4<!:%<;X` 8<!9 YH.10I B!Z2,.(G/_I-- d!'122,3 E&!*. ,-` ',G2(N/,A*H ,0) G,0G*2%U2(T T*G/,0IHTH .( ./*2,N*1.IG ITN-IG,.I(0H8&9` a2*0)H ]TT10(-!!"4:!%M#<$% !!X!!%X` 8<%9 ?1,I- Fd!&(3G* &K` 'IG2(*0_I2(0T*0.,- 2*A1-,.I(0 (U .1T(2 N2(A2*HHI(0 ,0) T*.,H.,HIH8&9` 7,. '*)!!"4%!4X#44$%4<!%!4<%$` 8<<9 B1UU*-- D!KUU,2, 7]!=(1HH*0H f'` FIUU*2*0.I,- T,G2(N/,A* N2(A2,TTI0A I0 ./* .1T(2 TIG2(*0_I2(0T*0.8&9` a2*0)H ]TT10(-!!"4!!%%#%$%44X!4!M` 8<:9 >*I0*2 f'!'122,3 &=!C/1N.2I0* =>` K0.I^()3!^,H*) ITT10(./*2,N3 (U G,0G*28&9` =*--!!"4!!4<;#M$%4";4!4";<` 8<M9 7ITT*2h,/0 d!e(2),0 C!f1S K` dG!B )*N*0)*0. T*G/,0IHTH (U G3.(! .(SIG!,A(0IH.IG!,0) 0*1.2,-IbI0A ,0.I^()3 ,G.I_I.I*H8&9` a2*0)H ]TT10(-! !"4:!%M#M$%%!:!%%M` 8<$9 =-30*H BK!a(R*2H af!E2*H., fe!*. ,-` ]0/I^I.(23 dG 2*G*N.(2H T()1-,.* I0 _I_( G3.(.(SIGI.3 ,A,I0H. .1T(2 .,2A*.H8&9` 7,. '*)!!"""!M#<$%<<%!<<M` 8<;9 'I0,2)!=(-I0 5!gI1 [!E(* &=!*. ,-` f3TN/(T, )*N-*.I(0 )12I0A =F!" ITT10(./*2,N3 I0 TIG* IH T*)I,.*) ^3 T,G2(N/,A*dGA,TT,B]!dGA,T! T,B]]]!,0) dGA,TT,B]58&9` D-(()!!"";!44!#<$%4!":!4!4%` 8<X9 Y..*0 'K!_,0 )*2 DIh e&!5*2^**\ C&!*. ,-` cSN*2IT*0.,- ,0.I^()3 ./*2! ,N3 (U -I_*2 T*.,H.,H*H 2*_*,-H U10G.I(0,- 2*)10),0G3 ^*.R**0 dG A,T! T,B] ,0) dG A,TT,B]58&9` & ]TT10(-!!"";!4;4#4"$%M;!X!M;%M` 8:"9 E,2\ C!&I,0A @!'(2.*0H(0 cF!*. ,-` a/* ./*2,N*1.IG *UU*G. (U ,0.I! +cB!P0*1 ,0.I^()3 )*N*0)H (0 ^(./ I00,.* ,0) ,),N.I_* ITT10I.3 8&9` =,0G*2 =*--!!"4"!4;#!$%4M"!4$"` 8:49 e21A,0 ZF!'G=,^* df!ZI0)*2 '!*. ,-` a1T(2!,HH(GI,.*) T,G2(N/,A*H N2(T(.* I0_,HI(0 R/I-* 2*.,I0I0A dG!)*N*0)*0. ,0.I!.1T(2 U10G.I(08&9` & ]TT10(-!!"4!!4;X#44$%:<:$!:<MM` #收稿日期%!"4M!"X!!:$ !上接第 4M; 页" '4$%(